* eFFECTOR Therapeutics Inc EFTR.OQ reported a quarterly
adjusted loss of 23 cents per share for the quarter ended in
September. The mean expectation of five analysts for the quarter
was for a loss of 21 cents per share.
* Revenue rose 103% to $867.00 thousand from a year ago;
analysts
expected $642.20 thousand.
* eFFECTOR Therapeutics Inc's reported EPS for the quarter
was a
loss of 23 cents.
* The mean earnings estimate of analysts had fallen by
about 23.6%
in the last three months.
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company.
* eFFECTOR Therapeutics Inc shares had fallen by 7.4% this
quarter and lost 93.6% so far this year.
* The company reported a quarterly loss of $9.55 million.
* Wall Street's median 12-month price target for eFFECTOR
Therapeutics Inc is $7.50
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
This summary was machine generated from Refinitiv data November
7 at 10:00 p.m. All figures in US dollars unless otherwise
stated. QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2022 -0.21 -0.23 Missed
Jun. 30 2022 -0.16 -0.17 Missed
Mar. 31 2022 -0.24 0.07 Beat
Dec. 31 2021 -0.24 0.44 Beat